Comparison · NCT00783263-cd07b0c8
Rosuvastatin (5 or 10 mg) + Ezetimibe 10 mg vs Rosuvastatin 10 or 20 mg: Number of Participants Who Reached the LDL-C Level of <70 mg/dl
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Rosuvastatin (5 or 10 mg) + Ezetimibe 10 mg vs Rosuvastatin 10 or 20 mg: Number of Participants Who Reached the LDL-C Level of <70 mg/dl. Trial comparisons, record NCT00783263-cd07b0c8. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00783263-cd07b0c8
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.438 | 0.374 | 0.505 | wilson | |
| Risk in group 2 | 0.175 | 0.13 | 0.231 | wilson | |
| Risk difference, group 1 minus group 2 | 0.263 | 0.178 | 0.343 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 2.5 | 1.81 | 3.47 | log | |
| Odds ratio, group 1 over group 2 | 3.68 | 2.37 | 5.71 | log | |
| Number needed to treat, for one more participant with the outcome on Rosuvastatin (5 or 10 mg) + Ezetimibe 10 mg than on Rosuvastatin 10 or 20 mg | 3.8 | 2.91 | 5.62 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Rosuvastatin (5 or 10 mg) + Ezetimibe 10 mg | Participants who received open label rosuvastatin 5 or 10 mg tablets once daily for 4 to 5 weeks then received 10 or 20 mg ezetimibe tablets once daily plus 5 mg rosuvastatin for an additional 6 weeks. | 96 | 219 | OG000 |
| Group 2 | Rosuvastatin 10 or 20 mg | Participants who received rosuvastatin (5 or 10 mg) tablets once daily for 4 to 5 weeks then received rosuvastatin (10 or 20 mg) once daily for 6 additional weeks. | 38 | 217 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants Who Reached the LDL-C Level of <70 mg/dl
- Description
Participants across all strata who reached the LDL-C Level of \<70 mg/dl after the addition of ezetimibe 10 mg to rosuvastatin (5 or 10 mg) daily for 6 weeks compared with doubling the baseline dose of rosuvastatin (10 or 20 mg) daily for 6 weeks.
- Time frame
- 6 weeks of treatment
- Population
Source ClinicalTrials.gov
Trial
- Title
- A Study of Ezetimibe Added On to Rosuvastatin Versus Up Titration of Rosuvastatin in Patients With Hypercholesterolemia (MK0653-139)
- NCT number
- NCT00783263
- Phases
- PHASE3
- Conditions
- Hypercholesterolemia
- Interventions
- Comparator: rosuvastatin 5 mg + ezetimibe 10 mg, Comparator: rosuvastatin 10 mg, Comparator: rosuvastatin 10 mg + ezetimibe 10 mg, Comparator: rosuvastatin 20 mg
- Lead sponsor
- Organon and Co
- Results first posted
- 2011-09-14
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00783263?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00783263-cd07b0c8